Results 141 to 150 of about 1,640,336 (314)

Cancer in sub-Saharan Africa: a Lancet Oncology Commission.

The Lancet Oncology, 2022
W. Ngwa, B. W. Addai, I. Adewole, V. Ainsworth, James Alaro, O. Alatise, Z. Ali, B. Anderson, R. Anorlu, S. Avery, P. Barango, N. Bih, C. Booth, O. Brawley, J. Dangou, L. Denny, J. Dent, S. Elmore, A. Elzawawy, Diane Gashumba, J. Geel, K. Graef, S. Gupta, S. Gueye, N. Hammad, L. Hessissen, André M. Ilbawi, J. Kambugu, Z. Kozlakidis, S. Manga, Lize Maree, S. Mohammed, S. Msadabwe, M. Mutebi, Annet Nakaganda, N. Ndlovu, Kingsley Ndoh, J. Ndumbalo, M. Ngoma, T. Ngoma, Christian Ntizimira, T. Rebbeck, L. Renner, A. Romanoff, F. Rubagumya, S. Sayed, S. Sud, H. Simonds, R. Sullivan, W. Swanson, V. Vanderpuye, Boateng Wiafe, David Kerr   +52 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Correction: Addendum of Informed Consent Statements [PDF]

Journal of Urologic Oncology
Editorial Office, Korean Urological Oncology Society
doaj   +1 more source

Author response for "Long‐Term Follow‐Up of Patients with Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Report from the Spanish Lymphoma Oncology Group"

, 2020
B. Núñez García, Marta Rodríguez‐Pertierra, Silvia Sequero, Laura Gálvez, Alberto Ruano‐Raviña, David Aguiar, Josep Gumá, Cristina Quero Blanco, Francisco Ramón García Arroyo, Yago Garitaonaindía, Zaida Provencio, Virginia Calvo, Carmen González‐San Segundo, Mariano Provencio   +13 more
openalex   +1 more source

OncoKB: A Precision Oncology Knowledge Base.

JCO Precision Oncology, 2017
D. Chakravarty, Jianjiong Gao, Sarah M. Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, J. Rudolph, R. Yaeger, Tara E. Soumerai, Moriah H. Nissan, Matthew T. Chang, S. Chandarlapaty, T. Traina, P. Paik, A. Ho, F. Hantash, A. Grupe, S. Baxi, M. Callahan, A. Snyder, Ping Chi, D. Danila, M. Gounder, J. Harding, M. Hellmann, G. Iyer, Y. Janjigian, T. Kaley, D. Levine, M. Lowery, A. Omuro, M. Postow, D. Rathkopf, A. Shoushtari, N. Shukla, M. Voss, Ederlinda Paraiso, A. Zehir, M. Berger, B. Taylor, L. Saltz, Gregory Riely, M. Ladanyi, D. Hyman, J. Baselga, P. Sabbatini, D. Solit, N. Schultz   +47 more
semanticscholar   +1 more source

Harnessing multimodal data integration to advance precision oncology

Nature Reviews. Cancer, 2021
K. Boehm, Pegah Khosravi, R. Vanguri, Jianjiong Gao, Sohrab P. Shah   +4 more
semanticscholar   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Expression of Concern: Rare Ewingoid Dedifferentiated Liposarcoma of the Spermatic Cord Causing Testicular Artery Compression: A Case Report [PDF]

Journal of Urologic Oncology
Editorial Office, Korean Urological Oncology Society
doaj   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source